lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people and communities, embed sustainability across its business, operate responsibly, and lead with integrity.
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases.
Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 2:30 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participants Eve Burstein - Bernstein Eve Burstein All right. Thank you so much, everyone, for joining.
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illumina's IVD portfolio will also expand to offer Pillar oncoRevealĀ® CDx, the newest panel to deliver critical companion diagnostic testing using the Illumina MiSeqā¢ Dx System SAN DIEGO , May 28, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more patients with cancer.
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (āSignios Bioā), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5Kā¢. Powered by SOMAmerĀ® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum. Illumina Protein Prep 9.5Kā¢ utilizes slow off-rate modified.
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisions Conference on May 28, 2025 Fireside chat at 11:30am Pacific Time (2:30pm Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.
Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illumina: Multiple Headwinds Point To Limited Upside In 2025
Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in line, but updated guidance predicts a revenue decline of 1%-3%, due to China headwinds and uncertain U.S. research funding. Despite a $100 million cost reduction program and ongoing R&D investments, Illumina's stock appears overvalued by nearly 18% based on a DCF analysis.
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips
ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.
